Article
Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Scientific reports - 19 Jun 2015
Li Song, Hou Huayan, Mori Takashi, Sawmiller Darrell, Smith Adam, Tian Jun, Wang Yanjiang, Giunta Brian, Sanberg Paul R, Zhang Sheqing, Tan Jun
Abstract excerpt
BACE1 initiates amyloid-β (Aβ) generation and the resultant cerebral amyloidosis, as a characteristic of Alzheimer's disease (AD). Thus, inhibition of BACE1 has been the focus of a large body of research. The most recent clinical trials highlight the difficulty involved in this type of anti-AD therapy as evidenced by side effects likely due to the ubiquitous nature of BACE1, which cleaves multiple substrates. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.